Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy

Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy

Lung cancer is the most common malignancy and is a major public health problem worldwide. Programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors provide a new treatment strategy for non-small cell lung cancer (NSCLC). The existing biomarkers all have advantages and...

Full description

Bibliographic Details
Main Authors: Wenjia SUN, Jianya ZHOU, Jianying ZHOU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-01-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
multiplex
immunohistochemistry
immunofluorescence
immunotherapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.47
id doaj-c0ac9ffacb814dd2a60b6acfab329d58
record_format Article
spelling doaj-c0ac9ffacb814dd2a60b6acfab329d582021-01-22T03:26:30ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872021-01-01241364210.3779/j.issn.1009-3419.2020.102.47Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer ImmunotherapyWenjia SUN0Jianya ZHOU1Jianying ZHOU2Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, 
Hangzhou 310000, ChinaDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, 
Hangzhou 310000, ChinaDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, 
Hangzhou 310000, ChinaLung cancer is the most common malignancy and is a major public health problem worldwide. Programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors provide a new treatment strategy for non-small cell lung cancer (NSCLC). The existing biomarkers all have advantages and defects in selecting patients who benefit from immunotherapy. The multiplex immunohistochemistry/immunofluorescence (mIHC/IF) provides multiplex staining, allows comprehensive studies of cellular composition, cellular functions and cell-cell interactions. A number of studies have used mIHC/IF to explore specific immune cells in tumor immune microenvironment (TIME) and found that it is helpful for clinical prognosis and efficacy prediction in patients with lung cancer. In the era of immunotherapy for lung cancer, this technique has a bright future in translational research and clinical practice. The research progress of mIHC/IF detection in lung cancer immunotherapy is summarized in this review.http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.47lung neoplasmsmultipleximmunohistochemistryimmunofluorescenceimmunotherapy
collection DOAJ
language zho
format Article
sources DOAJ
author Wenjia SUN
Jianya ZHOU
Jianying ZHOU
spellingShingle Wenjia SUN
Jianya ZHOU
Jianying ZHOU
Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy
Chinese Journal of Lung Cancer
lung neoplasms
multiplex
immunohistochemistry
immunofluorescence
immunotherapy
author_facet Wenjia SUN
Jianya ZHOU
Jianying ZHOU
author_sort Wenjia SUN
title Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy
title_short Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy
title_full Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy
title_fullStr Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy
title_full_unstemmed Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques 
in the Lung Cancer Immunotherapy
title_sort overview of multiplex immunohistochemistry and immunofluorescence techniques 
in the lung cancer immunotherapy
publisher Chinese Anti-Cancer Association; Chinese Antituberculosis Association
series Chinese Journal of Lung Cancer
issn 1009-3419
1999-6187
publishDate 2021-01-01
description Lung cancer is the most common malignancy and is a major public health problem worldwide. Programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors provide a new treatment strategy for non-small cell lung cancer (NSCLC). The existing biomarkers all have advantages and defects in selecting patients who benefit from immunotherapy. The multiplex immunohistochemistry/immunofluorescence (mIHC/IF) provides multiplex staining, allows comprehensive studies of cellular composition, cellular functions and cell-cell interactions. A number of studies have used mIHC/IF to explore specific immune cells in tumor immune microenvironment (TIME) and found that it is helpful for clinical prognosis and efficacy prediction in patients with lung cancer. In the era of immunotherapy for lung cancer, this technique has a bright future in translational research and clinical practice. The research progress of mIHC/IF detection in lung cancer immunotherapy is summarized in this review.
topic lung neoplasms
multiplex
immunohistochemistry
immunofluorescence
immunotherapy
url http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.47
work_keys_str_mv AT wenjiasun overviewofmultipleximmunohistochemistryandimmunofluorescencetechniquesinthelungcancerimmunotherapy
AT jianyazhou overviewofmultipleximmunohistochemistryandimmunofluorescencetechniquesinthelungcancerimmunotherapy
AT jianyingzhou overviewofmultipleximmunohistochemistryandimmunofluorescencetechniquesinthelungcancerimmunotherapy
_version_ 1724329277226221568

Similar Items